Literature DB >> 10320232

Heart-lung transplantation for primary pulmonary hypertension.

R I Whyte1, R C Robbins, J Altinger, C W Barlow, R Doyle, J Theodore, B A Reitz.   

Abstract

BACKGROUND: The operation of choice for primary pulmonary hypertension remains controversial, as heart-lung transplantation, single-lung transplantation, and double-lung transplantation have all been advocated.
METHODS: We reviewed our institution's experience with heart-lung transplantation for primary pulmonary hypertension.
RESULTS: Thirty-nine patients had heart-lung transplantation for primary pulmonary hypertension. Operative mortality rate was 18%, and actuarial survival was 72% at 1 year, 67% at 2 years, and 42% at 5 years. Freedom from obliterative bronchiolitis was 91% at 1 year, 83% at 2 years, and 70% at 5 years. Freedom from obliterative bronchiolitis-related death was 100% at 1 year, 90% at 2 years, and 87% at 5 years. Freedom from accelerated graft coronary disease was 92% at 5 years. The most frequent causes of death were infection, obliterative bronchiolitis, and accelerated graft coronary disease.
CONCLUSIONS: Heart-lung transplantation results in survival comparable to that reported for single or double lung transplantation. Obliterative bronchiolitis is a significant cause of late death but seems to occur less frequently with heart-lung transplantation than with lung transplantation alone. Accelerated coronary graft disease is rare in the first 5 years after transplantation.

Entities:  

Mesh:

Year:  1999        PMID: 10320232     DOI: 10.1016/s0003-4975(99)00176-9

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  2 in total

Review 1.  State of the Art of Combined Heart-Lung Transplantation for Advanced Cardiac and Pulmonary Dysfunction.

Authors:  Jay J Idrees; Gösta B Pettersson
Journal:  Curr Cardiol Rep       Date:  2016-04       Impact factor: 2.931

2.  Surgical treatment of pulmonary hypertension: Lung transplantation.

Authors:  Jason Long; Mark J Russo; Charlie Muller; Wickii T Vigneswaran
Journal:  Pulm Circ       Date:  2011 Jul-Sep       Impact factor: 3.017

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.